<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02151110</url>
  </required_header>
  <id_info>
    <org_study_id>D5100C00001</org_study_id>
    <nct_id>NCT02151110</nct_id>
  </id_info>
  <brief_title>Phase 1 Single-ascending Dose Study to Evaluate Safety and Tolerability of MEDI4920 in Healthy Adults</brief_title>
  <official_title>A Phase 1, Randomized, Blinded, Placebo-controlled, Single-ascending Dose Study to Evaluate the Safety and Tolerability of MEDI4920 in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1 single IV dose study to evaluate safety and tolerability of MEDI4920
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 27, 2014</start_date>
  <completion_date type="Actual">May 9, 2016</completion_date>
  <primary_completion_date type="Actual">May 9, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)</measure>
    <time_frame>The start of study drug administration (Day 1) to the follow-up period (Day 113) or early discontinuation visit</time_frame>
    <description>An adverse event (AE) is any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening situation (immediate risk of dying); persistent or significant disability or incapacity; congenital anomaly or birth defect in the offspring of a participant who received the study drug. A TEAE is defined as the event with onset after the start of infusion (Day 1) to Day 113 or early discontinuation visit inclusive. The AEs were summarized using Medical Dictionary for Regulatory Activities version 19.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of MEDI4920</measure>
    <time_frame>Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first</time_frame>
    <description>The maximum observed plasma concentration (Cmax) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-last) of MEDI4920</measure>
    <time_frame>Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first</time_frame>
    <description>The area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUC0-last) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MEDI4920</measure>
    <time_frame>Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first</time_frame>
    <description>The area under the plasma concentration-time curve from time zero to infinity (AUC 0-inf) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-normalized AUC0-inf (AUC0-infinity/D) of MEDI4920</measure>
    <time_frame>Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first</time_frame>
    <description>The AUC (0-infinity)/D is the area under concentration-time curve extrapolated to infinity postdose normalized by MEDI4920 dose. The AUC (0-infinity)/D was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half Life (t1/2) of MEDI4920</measure>
    <time_frame>Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first</time_frame>
    <description>The terminal elimination half-life (t1/2) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance (CL) of MEDI4920</measure>
    <time_frame>Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first</time_frame>
    <description>The systemic clearance (CL) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady-state (Vss) of MEDI4920</measure>
    <time_frame>Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first</time_frame>
    <description>The volume of distribution at steady-state (Vss) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution Based on Terminal Phase (Vz) of MEDI4920</measure>
    <time_frame>Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first</time_frame>
    <description>The volume of distribution based on terminal phase (Vz) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Positive for Anti-drug Antibodies (ADA)</measure>
    <time_frame>Baseline (pre-infusion on Day 1) and post-baseline Days 15, 29, 57, and 113 or early discontinuation visit, whichever occurred first</time_frame>
    <description>Plasma samples were collected for assessment of anti-drug antibodies (ADA) against MEDI4920. The incidence of positive serum antibodies to MEDI4920 are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-cell Dependent Antibody Response (TDAR) Measured by Anti-keyhole Limpet Hemocyanin Immunoglobulin G (Anti-KLH IgG) Concentration</measure>
    <time_frame>Day 43</time_frame>
    <description>The T-cell dependent antibody response (TDAR) assay measures the immune response (ie, antibody production) to an introduced antigen, keyhole limpet hemocyanin (KLH). The KLH is a potent immunostimulating protein with an extensive history of safe and effective use in vaccine development and immunological research. TDAR was evaluated by measuring anti-KLH IgG titers at a time point consistent with the expected timing for antibody responses following immunization. The primary time point for the analysis of the TDAR to KLH was Day 43. The data was presented for geometric mean ratio (MEDI4920/placebo) estimated from the dose response model.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received single IV dose of placebo matching with MEDI4920 infused on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI4920 3 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI4920 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received single IV dose of MEDI4920 10 mg infused on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI4920 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received single IV dose of MEDI4920 30 mg infused on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI4920 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received single IV dose of MEDI4920 100 mg infused on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI4920 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received single IV dose of MEDI4920 300 mg infused on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI4920 1000 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI4920 3000 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI4920 3 mg</intervention_name>
    <description>Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.</description>
    <arm_group_label>MEDI4920 3 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI4920 10 mg</intervention_name>
    <description>Participants received single IV dose of MEDI4920 10 mg infused on Day 1.</description>
    <arm_group_label>MEDI4920 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI4920 30 mg</intervention_name>
    <description>Participants received single IV dose of MEDI4920 30 mg infused on Day 1.</description>
    <arm_group_label>MEDI4920 30 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI4920 100 mg</intervention_name>
    <description>Participants received single IV dose of MEDI4920 100 mg infused on Day 1.</description>
    <arm_group_label>MEDI4920 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI4920 300 mg</intervention_name>
    <description>Participants received single IV dose of MEDI4920 300 mg infused on Day 1.</description>
    <arm_group_label>MEDI4920 300 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI4920 1000 mg</intervention_name>
    <description>Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.</description>
    <arm_group_label>MEDI4920 1000 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI4920 3000 mg</intervention_name>
    <description>Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.</description>
    <arm_group_label>MEDI4920 3000 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants received single IV dose of placebo matching with MEDI4920 infused on Day 1.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy as determined by a responsible study physician based on medical evaluation

          -  Body weight 40 to 100 kg

          -  Body mass index 19.0 to 30.0 kg/m2

        Exclusion Criteria:

          -  History of allergy or sensitivity to Shellfish or protein based antigens

          -  previous immunization with KLH

          -  previous splenectomy

          -  History of diagnosed or suspected thromboembolic event or coagulation disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>May 27, 2014</study_first_submitted>
  <study_first_submitted_qc>May 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2014</study_first_posted>
  <results_first_submitted>May 24, 2017</results_first_submitted>
  <results_first_submitted_qc>October 2, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 15, 2019</results_first_posted>
  <last_update_submitted>October 2, 2018</last_update_submitted>
  <last_update_submitted_qc>October 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Male</keyword>
  <keyword>Healthy Female of non child bearing potential</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Healthy adult male and female participants were recruited in a blinded manner. The study was conducted at one site in the United Kingdom.</recruitment_details>
      <pre_assignment_details>A total of 259 participants were screened of which 200 participants were considered screen failures and the remaining 59 participants were randomized. Out of which, 56 participants were treated</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received single IV dose of placebo matching with MEDI4920 infused on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>MEDI4920 3 mg</title>
          <description>Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>MEDI4920 10 mg</title>
          <description>Participants received single IV dose of MEDI4920 10 mg infused on Day 1.</description>
        </group>
        <group group_id="P4">
          <title>MEDI4920 30 mg</title>
          <description>Participants received single IV dose of MEDI4920 30 mg infused on Day 1.</description>
        </group>
        <group group_id="P5">
          <title>MEDI4920 100 mg</title>
          <description>Participants received single IV dose of MEDI4920 100 mg infused on Day 1.</description>
        </group>
        <group group_id="P6">
          <title>MEDI4920 300 mg</title>
          <description>Participants received single IV dose of MEDI4920 300 mg infused on Day 1.</description>
        </group>
        <group group_id="P7">
          <title>MEDI4920 1000 mg</title>
          <description>Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.</description>
        </group>
        <group group_id="P8">
          <title>MEDI4920 3000 mg</title>
          <description>Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>As-treated population included all participants who received any study drug. Two participants were erroneously randomized to MEDI4920 10 mg group due to the IXRS system not being opened for start of MEDI4920 30 mg group. However, these participants received the 30 mg dose.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received single IV dose of placebo matching with MEDI4920 infused on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>MEDI4920 3 mg</title>
          <description>Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>MEDI4920 10 mg</title>
          <description>Participants received single IV dose of MEDI4920 10 mg infused on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>MEDI4920 30 mg</title>
          <description>Participants received single IV dose of MEDI4920 30 mg infused on Day 1.</description>
        </group>
        <group group_id="B5">
          <title>MEDI4920 100 mg</title>
          <description>Participants received single IV dose of MEDI4920 100 mg infused on Day 1.</description>
        </group>
        <group group_id="B6">
          <title>MEDI4920 300 mg</title>
          <description>Participants received single IV dose of MEDI4920 300 mg infused on Day 1.</description>
        </group>
        <group group_id="B7">
          <title>MEDI4920 1000 mg</title>
          <description>Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.</description>
        </group>
        <group group_id="B8">
          <title>MEDI4920 3000 mg</title>
          <description>Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.</description>
        </group>
        <group group_id="B9">
          <title>TOTAL</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="2"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="8"/>
            <count group_id="B7" value="8"/>
            <count group_id="B8" value="8"/>
            <count group_id="B9" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.3" spread="8.9"/>
                    <measurement group_id="B2" value="27.5" spread="4.9"/>
                    <measurement group_id="B3" value="26.0" spread="1.4"/>
                    <measurement group_id="B4" value="27.8" spread="12.3"/>
                    <measurement group_id="B5" value="28.1" spread="10.1"/>
                    <measurement group_id="B6" value="38.4" spread="9.3"/>
                    <measurement group_id="B7" value="33.3" spread="9.2"/>
                    <measurement group_id="B8" value="32.0" spread="9.8"/>
                    <measurement group_id="B9" value="31.8" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)</title>
        <description>An adverse event (AE) is any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening situation (immediate risk of dying); persistent or significant disability or incapacity; congenital anomaly or birth defect in the offspring of a participant who received the study drug. A TEAE is defined as the event with onset after the start of infusion (Day 1) to Day 113 or early discontinuation visit inclusive. The AEs were summarized using Medical Dictionary for Regulatory Activities version 19.0.</description>
        <time_frame>The start of study drug administration (Day 1) to the follow-up period (Day 113) or early discontinuation visit</time_frame>
        <population>As-treated Population: All participants who received any study drug were included in this population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received single IV dose of placebo matching with MEDI4920 infused on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI4920 3 mg</title>
            <description>Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI4920 10 mg</title>
            <description>Participants received single IV dose of MEDI4920 10 mg infused on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI4920 30 mg</title>
            <description>Participants received single IV dose of MEDI4920 30 mg infused on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI4920 100 mg</title>
            <description>Participants received single IV dose of MEDI4920 100 mg infused on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MEDI4920 300 mg</title>
            <description>Participants received single IV dose of MEDI4920 300 mg infused on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MEDI4920 1000 mg</title>
            <description>Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>MEDI4920 3000 mg</title>
            <description>Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)</title>
          <description>An adverse event (AE) is any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening situation (immediate risk of dying); persistent or significant disability or incapacity; congenital anomaly or birth defect in the offspring of a participant who received the study drug. A TEAE is defined as the event with onset after the start of infusion (Day 1) to Day 113 or early discontinuation visit inclusive. The AEs were summarized using Medical Dictionary for Regulatory Activities version 19.0.</description>
          <population>As-treated Population: All participants who received any study drug were included in this population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TESAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) of MEDI4920</title>
        <description>The maximum observed plasma concentration (Cmax) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.</description>
        <time_frame>Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first</time_frame>
        <population>As-treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI4920 3 mg</title>
            <description>Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI4920 10 mg</title>
            <description>Participants received single IV dose of MEDI4920 10 mg infused on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI4920 30 mg</title>
            <description>Participants received single IV dose of MEDI4920 30 mg infused on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI4920 100 mg</title>
            <description>Participants received single IV dose of MEDI4920 100 mg infused on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI4920 300 mg</title>
            <description>Participants received single IV dose of MEDI4920 300 mg infused on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MEDI4920 1000 mg</title>
            <description>Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MEDI4920 3000 mg</title>
            <description>Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) of MEDI4920</title>
          <description>The maximum observed plasma concentration (Cmax) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.</description>
          <population>As-treated Population</population>
          <units>microgram per milliliter (µg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="NA">Not calculated; Standard deviation was only calculated if N &gt;= 3.</measurement>
                    <measurement group_id="O2" value="4.46" spread="NA">Not calculated; Standard deviation was only calculated if N &gt;= 3.</measurement>
                    <measurement group_id="O3" value="7.97" spread="0.873"/>
                    <measurement group_id="O4" value="23.6" spread="2.76"/>
                    <measurement group_id="O5" value="85.6" spread="17.6"/>
                    <measurement group_id="O6" value="289" spread="58.1"/>
                    <measurement group_id="O7" value="960" spread="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-last) of MEDI4920</title>
        <description>The area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUC0-last) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.</description>
        <time_frame>Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first</time_frame>
        <population>As-treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI4920 3 mg</title>
            <description>Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI4920 10 mg</title>
            <description>Participants received single IV dose of MEDI4920 10 mg infused on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI4920 30 mg</title>
            <description>Participants received single IV dose of MEDI4920 30 mg infused on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI4920 100 mg</title>
            <description>Participants received single IV dose of MEDI4920 100 mg infused on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI4920 300 mg</title>
            <description>Participants received single IV dose of MEDI4920 300 mg infused on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MEDI4920 1000 mg</title>
            <description>Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MEDI4920 3000 mg</title>
            <description>Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-last) of MEDI4920</title>
          <description>The area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUC0-last) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.</description>
          <population>As-treated Population</population>
          <units>microgram*day per milliliter (µg*d/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.64" spread="NA">Not calculated; Standard deviation was only calculated if N &gt;= 3.</measurement>
                    <measurement group_id="O2" value="19.3" spread="NA">Not calculated; Standard deviation was only calculated if N &gt;= 3.</measurement>
                    <measurement group_id="O3" value="53.4" spread="10.9"/>
                    <measurement group_id="O4" value="151" spread="20.2"/>
                    <measurement group_id="O5" value="581" spread="38.3"/>
                    <measurement group_id="O6" value="2090" spread="394"/>
                    <measurement group_id="O7" value="6640" spread="553"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MEDI4920</title>
        <description>The area under the plasma concentration-time curve from time zero to infinity (AUC 0-inf) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.</description>
        <time_frame>Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first</time_frame>
        <population>As-treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI4920 3 mg</title>
            <description>Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI4920 10 mg</title>
            <description>Participants received single IV dose of MEDI4920 10 mg infused on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI4920 30 mg</title>
            <description>Participants received single IV dose of MEDI4920 30 mg infused on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI4920 100 mg</title>
            <description>Participants received single IV dose of MEDI4920 100 mg infused on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI4920 300 mg</title>
            <description>Participants received single IV dose of MEDI4920 300 mg infused on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MEDI4920 1000 mg</title>
            <description>Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MEDI4920 3000 mg</title>
            <description>Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MEDI4920</title>
          <description>The area under the plasma concentration-time curve from time zero to infinity (AUC 0-inf) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.</description>
          <population>As-treated Population</population>
          <units>microgram*day per milliliter (µg*d/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.60" spread="NA">Not calculated; Standard deviation was only calculated if N &gt;= 3.</measurement>
                    <measurement group_id="O2" value="20.5" spread="NA">Not calculated; Standard deviation was only calculated if N &gt;= 3.</measurement>
                    <measurement group_id="O3" value="54.8" spread="11.0"/>
                    <measurement group_id="O4" value="152" spread="20.2"/>
                    <measurement group_id="O5" value="583" spread="37.8"/>
                    <measurement group_id="O6" value="2090" spread="394"/>
                    <measurement group_id="O7" value="6640" spread="547"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dose-normalized AUC0-inf (AUC0-infinity/D) of MEDI4920</title>
        <description>The AUC (0-infinity)/D is the area under concentration-time curve extrapolated to infinity postdose normalized by MEDI4920 dose. The AUC (0-infinity)/D was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.</description>
        <time_frame>Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first</time_frame>
        <population>As-treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI4920 3 mg</title>
            <description>Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI4920 10 mg</title>
            <description>Participants received single IV dose of MEDI4920 10 mg infused on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI4920 30 mg</title>
            <description>Participants received single IV dose of MEDI4920 30 mg infused on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI4920 100 mg</title>
            <description>Participants received single IV dose of MEDI4920 100 mg infused on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI4920 300 mg</title>
            <description>Participants received single IV dose of MEDI4920 300 mg infused on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MEDI4920 1000 mg</title>
            <description>Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MEDI4920 3000 mg</title>
            <description>Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-normalized AUC0-inf (AUC0-infinity/D) of MEDI4920</title>
          <description>The AUC (0-infinity)/D is the area under concentration-time curve extrapolated to infinity postdose normalized by MEDI4920 dose. The AUC (0-infinity)/D was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.</description>
          <population>As-treated Population</population>
          <units>µg*d/mL/mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" spread="NA">Not calculated; Standard deviation was only calculated if N &gt;= 3.</measurement>
                    <measurement group_id="O2" value="2.05" spread="NA">Not calculated; Standard deviation was only calculated if N &gt;= 3.</measurement>
                    <measurement group_id="O3" value="1.83" spread="0.366"/>
                    <measurement group_id="O4" value="1.52" spread="0.202"/>
                    <measurement group_id="O5" value="1.94" spread="0.126"/>
                    <measurement group_id="O6" value="2.09" spread="0.394"/>
                    <measurement group_id="O7" value="2.21" spread="0.182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Half Life (t1/2) of MEDI4920</title>
        <description>The terminal elimination half-life (t1/2) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.</description>
        <time_frame>Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first</time_frame>
        <population>As-treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI4920 3 mg</title>
            <description>Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI4920 10 mg</title>
            <description>Participants received single IV dose of MEDI4920 10 mg infused on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI4920 30 mg</title>
            <description>Participants received single IV dose of MEDI4920 30 mg infused on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI4920 100 mg</title>
            <description>Participants received single IV dose of MEDI4920 100 mg infused on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI4920 300 mg</title>
            <description>Participants received single IV dose of MEDI4920 300 mg infused on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MEDI4920 1000 mg</title>
            <description>Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MEDI4920 3000 mg</title>
            <description>Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half Life (t1/2) of MEDI4920</title>
          <description>The terminal elimination half-life (t1/2) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.</description>
          <population>As-treated Population</population>
          <units>Day(s)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.41" spread="NA">Not calculated; Standard deviation was only calculated if N &gt;= 3.</measurement>
                    <measurement group_id="O2" value="5.35" spread="NA">Not calculated; Standard deviation was only calculated if N &gt;= 3.</measurement>
                    <measurement group_id="O3" value="5.31" spread="2.30"/>
                    <measurement group_id="O4" value="5.49" spread="1.59"/>
                    <measurement group_id="O5" value="8.86" spread="1.60"/>
                    <measurement group_id="O6" value="9.68" spread="1.25"/>
                    <measurement group_id="O7" value="10.1" spread="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systemic Clearance (CL) of MEDI4920</title>
        <description>The systemic clearance (CL) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.</description>
        <time_frame>Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first</time_frame>
        <population>As-treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI4920 3 mg</title>
            <description>Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI4920 10 mg</title>
            <description>Participants received single IV dose of MEDI4920 10 mg infused on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI4920 30 mg</title>
            <description>Participants received single IV dose of MEDI4920 30 mg infused on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI4920 100 mg</title>
            <description>Participants received single IV dose of MEDI4920 100 mg infused on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI4920 300 mg</title>
            <description>Participants received single IV dose of MEDI4920 300 mg infused on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MEDI4920 1000 mg</title>
            <description>Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MEDI4920 3000 mg</title>
            <description>Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Systemic Clearance (CL) of MEDI4920</title>
          <description>The systemic clearance (CL) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.</description>
          <population>As-treated Population</population>
          <units>milliliter per day (mL/day)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="661" spread="NA">Not calculated; Standard deviation was only calculated if N &gt;= 3.</measurement>
                    <measurement group_id="O2" value="487" spread="NA">Not calculated; Standard deviation was only calculated if N &gt;= 3.</measurement>
                    <measurement group_id="O3" value="564" spread="96.8"/>
                    <measurement group_id="O4" value="668" spread="90.4"/>
                    <measurement group_id="O5" value="517" spread="33.5"/>
                    <measurement group_id="O6" value="494" spread="102"/>
                    <measurement group_id="O7" value="454" spread="37.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution at Steady-state (Vss) of MEDI4920</title>
        <description>The volume of distribution at steady-state (Vss) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.</description>
        <time_frame>Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first</time_frame>
        <population>As-treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI4920 3 mg</title>
            <description>Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI4920 10 mg</title>
            <description>Participants received single IV dose of MEDI4920 10 mg infused on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI4920 30 mg</title>
            <description>Participants received single IV dose of MEDI4920 30 mg infused on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI4920 100 mg</title>
            <description>Participants received single IV dose of MEDI4920 100 mg infused on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI4920 300 mg</title>
            <description>Participants received single IV dose of MEDI4920 300 mg infused on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MEDI4920 1000 mg</title>
            <description>Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MEDI4920 3000 mg</title>
            <description>Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution at Steady-state (Vss) of MEDI4920</title>
          <description>The volume of distribution at steady-state (Vss) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.</description>
          <population>As-treated Population</population>
          <units>milliliter (mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3980" spread="NA">Not calculated; Standard deviation was only calculated if N &gt;= 3.</measurement>
                    <measurement group_id="O2" value="3290" spread="NA">Not calculated; Standard deviation was only calculated if N &gt;= 3.</measurement>
                    <measurement group_id="O3" value="4280" spread="684"/>
                    <measurement group_id="O4" value="5560" spread="806"/>
                    <measurement group_id="O5" value="5180" spread="811"/>
                    <measurement group_id="O6" value="5450" spread="1150"/>
                    <measurement group_id="O7" value="4900" spread="715"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution Based on Terminal Phase (Vz) of MEDI4920</title>
        <description>The volume of distribution based on terminal phase (Vz) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.</description>
        <time_frame>Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first</time_frame>
        <population>As-treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI4920 3 mg</title>
            <description>Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI4920 10 mg</title>
            <description>Participants received single IV dose of MEDI4920 10 mg infused on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI4920 30 mg</title>
            <description>Participants received single IV dose of MEDI4920 30 mg infused on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI4920 100 mg</title>
            <description>Participants received single IV dose of MEDI4920 100 mg infused on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI4920 300 mg</title>
            <description>Participants received single IV dose of MEDI4920 300 mg infused on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MEDI4920 1000 mg</title>
            <description>Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MEDI4920 3000 mg</title>
            <description>Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution Based on Terminal Phase (Vz) of MEDI4920</title>
          <description>The volume of distribution based on terminal phase (Vz) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.</description>
          <population>As-treated Population</population>
          <units>milliliter (mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4130" spread="NA">Not calculated; Standard deviation was only calculated if N &gt;= 3.</measurement>
                    <measurement group_id="O2" value="3760" spread="NA">Not calculated; Standard deviation was only calculated if N &gt;= 3.</measurement>
                    <measurement group_id="O3" value="4080" spread="1090"/>
                    <measurement group_id="O4" value="5230" spread="1360"/>
                    <measurement group_id="O5" value="6590" spread="1160"/>
                    <measurement group_id="O6" value="6880" spread="1520"/>
                    <measurement group_id="O7" value="6600" spread="1190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Positive for Anti-drug Antibodies (ADA)</title>
        <description>Plasma samples were collected for assessment of anti-drug antibodies (ADA) against MEDI4920. The incidence of positive serum antibodies to MEDI4920 are presented.</description>
        <time_frame>Baseline (pre-infusion on Day 1) and post-baseline Days 15, 29, 57, and 113 or early discontinuation visit, whichever occurred first</time_frame>
        <population>As-treated Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received single IV dose of placebo matching with MEDI4920 infused on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI4920 3 mg</title>
            <description>Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI4920 10 mg</title>
            <description>Participants received single IV dose of MEDI4920 10 mg infused on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI4920 30 mg</title>
            <description>Participants received single IV dose of MEDI4920 30 mg infused on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI4920 100 mg</title>
            <description>Participants received single IV dose of MEDI4920 100 mg infused on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MEDI4920 300 mg</title>
            <description>Participants received single IV dose of MEDI4920 300 mg infused on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MEDI4920 1000 mg</title>
            <description>Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>MEDI4920 3000 mg</title>
            <description>Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Positive for Anti-drug Antibodies (ADA)</title>
          <description>Plasma samples were collected for assessment of anti-drug antibodies (ADA) against MEDI4920. The incidence of positive serum antibodies to MEDI4920 are presented.</description>
          <population>As-treated Population.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline ADA positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-baseline ADA positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="100"/>
                    <measurement group_id="O5" value="87.5"/>
                    <measurement group_id="O6" value="37.5"/>
                    <measurement group_id="O7" value="37.5"/>
                    <measurement group_id="O8" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T-cell Dependent Antibody Response (TDAR) Measured by Anti-keyhole Limpet Hemocyanin Immunoglobulin G (Anti-KLH IgG) Concentration</title>
        <description>The T-cell dependent antibody response (TDAR) assay measures the immune response (ie, antibody production) to an introduced antigen, keyhole limpet hemocyanin (KLH). The KLH is a potent immunostimulating protein with an extensive history of safe and effective use in vaccine development and immunological research. TDAR was evaluated by measuring anti-KLH IgG titers at a time point consistent with the expected timing for antibody responses following immunization. The primary time point for the analysis of the TDAR to KLH was Day 43. The data was presented for geometric mean ratio (MEDI4920/placebo) estimated from the dose response model.</description>
        <time_frame>Day 43</time_frame>
        <population>As-treated Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received single IV dose of placebo matching with MEDI4920 infused on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI4920 3 mg</title>
            <description>Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI4920 10 mg</title>
            <description>Participants received single IV dose of MEDI4920 10 mg infused on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI4920 30 mg</title>
            <description>Participants received single IV dose of MEDI4920 30 mg infused on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI4920 100 mg</title>
            <description>Participants received single IV dose of MEDI4920 100 mg infused on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MEDI4920 300 mg</title>
            <description>Participants received single IV dose of MEDI4920 300 mg infused on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MEDI4920 1000 mg</title>
            <description>Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>MEDI4920 3000 mg</title>
            <description>Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>T-cell Dependent Antibody Response (TDAR) Measured by Anti-keyhole Limpet Hemocyanin Immunoglobulin G (Anti-KLH IgG) Concentration</title>
          <description>The T-cell dependent antibody response (TDAR) assay measures the immune response (ie, antibody production) to an introduced antigen, keyhole limpet hemocyanin (KLH). The KLH is a potent immunostimulating protein with an extensive history of safe and effective use in vaccine development and immunological research. TDAR was evaluated by measuring anti-KLH IgG titers at a time point consistent with the expected timing for antibody responses following immunization. The primary time point for the analysis of the TDAR to KLH was Day 43. The data was presented for geometric mean ratio (MEDI4920/placebo) estimated from the dose response model.</description>
          <population>As-treated Population.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Geometric mean ratio and 95% CI were not estimated for placebo, as the estimation was performed using the dose response model which only applies to participants who received MEDI4920.</measurement>
                    <measurement group_id="O2" value="0.99" lower_limit="0.96" upper_limit="1.01"/>
                    <measurement group_id="O3" value="0.96" lower_limit="0.89" upper_limit="1.03"/>
                    <measurement group_id="O4" value="0.88" lower_limit="0.72" upper_limit="1.08"/>
                    <measurement group_id="O5" value="0.68" lower_limit="0.41" upper_limit="1.14"/>
                    <measurement group_id="O6" value="0.42" lower_limit="0.18" upper_limit="0.97"/>
                    <measurement group_id="O7" value="0.22" lower_limit="0.10" upper_limit="0.47"/>
                    <measurement group_id="O8" value="0.14" lower_limit="0.06" upper_limit="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from time of signature of informed consent, throughout the treatment period, and the follow-up period (through Day 113 or early discontinuation visit).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received single IV dose of placebo matching with MEDI4920 infused on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>MEDI4920 3 mg</title>
          <description>Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>MEDI4920 10 mg</title>
          <description>Participants received single IV dose of MEDI4920 10 mg infused on Day 1.</description>
        </group>
        <group group_id="E4">
          <title>MEDI4920 30 mg</title>
          <description>Participants received single IV dose of MEDI4920 30 mg infused on Day 1.</description>
        </group>
        <group group_id="E5">
          <title>MEDI4920 100 mg</title>
          <description>Participants received single IV dose of MEDI4920 100 mg infused on Day 1.</description>
        </group>
        <group group_id="E6">
          <title>MEDI4920 300 mg</title>
          <description>Participants received single IV dose of MEDI4920 300 mg infused on Day 1.</description>
        </group>
        <group group_id="E7">
          <title>MEDI4920 1000 mg</title>
          <description>Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.</description>
        </group>
        <group group_id="E8">
          <title>MEDI4920 3000 mg</title>
          <description>Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Eye inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Howe, MBChB, MD, MRCOG</name_or_title>
      <organization>MedImmune LLC</organization>
      <phone>+44 (0) 1223 895980</phone>
      <email>information.center@astrazenea.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

